DRG Knows Multiple Sclerosis
p
16
p
p
24
p
p
4
20
12
p
8
What impact will the launch of generic glatiramer acetate have on current therapies?
4 DRG Knows Multiple Sclerosis
COPAXONE ORALS
GENERIC GLATIRAMER ACETATE
INTERFERON-BETA
TYSABRI
In this safety-conscious prescriber base, time-tested Copaxone and the interferonbetas have remained dominant in the face of increasing competition from oral challengers, which supports the opportunity for a moreaffordable version of a key clinical mainstay. DRG Knows M ultiple Sclerosis 5
DATA Just under half of neurologists have reported being comfortable prescribing generic glatiramer acetate in place of branded Copaxone.
More than a quarter of neurologists report not being comfortable prescribing generic glatiramer acetate in place of branded Copaxone.
6 DRG Knows Multiple Sclerosis
INSIGHT While U.S. neurologists are concerned about patient out-of-pocket costs and half state that they are comfortable prescribing a generic version of branded Copaxone, the growing transition of patients to Copaxone 40 mg (three-times weekly), competition from oral agents, and potential physician resistance may blunt the impact of generic glatiramer acetate (20 mg) on the broader MS market.
SOLUTION
FEATURES
BENEFITS
Our suite of solutions for staying on top of the MS market include:
Actionable data, analytics, and insights enable you to keep your finger on the pulse of what’s relevant to you in the MS market.
»» Primary market research »» Market access insight
»» Enables informed decision making »» Efficiently assess market scenarios »» Partnership with expert analysts
p
35
Physician & Payer Forum Physician and Payer Market Access Insights
p
37
TreatmentTrends Analyzing Attitudes, Perceptions, and Prescribing Behavior DRG Knows M ultiple Sclerosis 7
What impact will the launch of generic glatiramer acetate have on neurologists’ prescribing?
8 DRG Knows Multiple Sclerosis
$
As the first generic to launch in this high-cost, brand-only market, glatiramer acetate represents a formidable disruption that will influence prescribing freedom and treatment choice.
?
? DRG Knows M ultiple Sclerosis 9
DATA Research shows that candidates for generic glatiramer acetate are significantly more likely than non-candidates to be on first-line therapy.
Candidates for generic glatiramer acetate are also significantly more likely than non-candidates to be on Copaxone 20 mg.
ChartTrends: MS US 2014 fielded April 3 – May 1, 2014
10 DRG Knows Multiple Sclerosis
INSIGHT The most immediate impact of generic glatiramer acetate will be felt in current Copaxone 20 mg-treated patients and in newly diagnosed patients, contributing to a sustained earlyline role for this injectable mainstay. With further clinical experience with oral competitors, neurologists may prefer to use these drugs earlier in the treatment algorithm, setting up more direct competition between generic glatiramer acetate and oral therapies.
SOLUTION
FEATURES
BENEFITS
Our suite of solutions for staying on top of the MS market include:
Actionable data, analytics, and insights enable you to keep your finger on the pulse of what’s relevant to you in the MS market.
»» Primary market research »» Patient chart audits »» Patient-level market forecasting
»» Enables informed decision making »» Efficiently assess market scenarios »» Partnership with expert analysts
p
34
Pharmacor Analyzing and Forecasting
p
30
ChartTrends Analyzing Patient-Level Data
DRG Knows M ultiple Sclerosis 11
What impact will the launch of generic glatiramer acetate have on the MS treatment algorithm? 12 DRG Knows Multiple Sclerosis
In the absence of generics, claims data show a decline in Copaxone 20 mg total patient share and first-line patient share in light of competition from oral agents; further competition has since come from Copaxone 40 mg. These forces will impact the immediate switch pool for generic glatiramer acetate.
DRG Knows M ultiple Sclerosis 13
DATA
INSIGHT
Through Q4 2013, Copaxone 20 mg still commanded 40% of first-line patient share in MS patients who were newly diagnosed in H2 2012 and followed over the course of a year. After only ~9 months on the market, Tecfidera garnered the highest patient shares in the second and third lines.
Despite contracting patient shares for Copaxone 20 mg today, payers may force switches to the generic and force newly diagnosed MS patients to step through generic glatiramer acetate before moving to a second-line therapy, potentially expanding first-line reliance on the molecule. In light of current switching patterns away from first-line Copaxone 20 mg, therapies least affected from greater entrenchment of glatiramer acetate include oral therapies, primarily Tecfidera.
Among the few newly diagnosed patients progressing to second-line therapy from Copaxone 20 mg within one year of diagnosis, the highest percentage switch to an oral therapy, mostly Tecfidera.
14 DRG Knows Multiple Sclerosis
SOLUTION
FEATURES
BENEFITS
Our suite of solutions for staying on top of the MS market include:
Actionable data, analytics, and insights enable you to keep your finger on the pulse of what’s relevant to you in the MS market.
»» Expert and timely forecasting »» Primary market research »» Payer claims analysis »» Market access insight
p
36
»» Enables informed decision making »» Efficiently assess market scenarios »» Partnership with expert analysts
Treatment Algorithms Quantifying Lines of Therapy
DRG Knows M ultiple Sclerosis 15
What impact will the launch of generic glatiramer acetate have on reimbursement conditions for MS drugs? 16 DRG Knows Multiple Sclerosis
As payers strive to draw out value for money in tough economic times, the first generic launch in a high-cost specialty drug market presents a pertinent opportunity for cost containment.
DRG Knows M ultiple Sclerosis 17
DATA
INSIGHT
An interviewed quality director reports that, as specialty drugs, Copaxone and generic glatiramer acetate will both be tier 4 in his healthcare plan. Depending on price relative to the brand, however, step edit through the generic version before use of Copaxone or other brands is likely.
The discount offered on generic glatiramer acetate relative to branded Copaxone will be pivotal to reimbursement conditions (including step therapy and cost-share requirements) for all key MS brands. However, our data indicates that the requirement for highly individualized treatment of MS patients will be a prime lever for maintaining formulary status quo, even on exchange-based plans, which represent a growth opportunity for marketers of MS therapies given the patient demographic.
Surveyed MCO directors report little difference between coverage of MS drugs on their exchange -based versus commercial plans currently. The need for individualized treatment of MS patients will likely see this trend remain following market penetration of generic glatiramer acetate.
18 DRG Knows Multiple Sclerosis
SOLUTION
FEATURES
BENEFITS
Our suite of solutions for staying on top of the MS market include:
Actionable data, analytics, and insights enable you to keep your finger on the pulse of what’s relevant to you in the MS market.
»» Primary market research »» Market access insight
»» Enables informed decision making »» Efficiently assess market scenarios »» Partnership with expert analysts
p
35
Physician & Payer Forum Physician and Payer Market Access Insights
p
30
ChartTrends Analyzing Patient-Level Data
DRG Knows M ultiple Sclerosis 19
What impact will the launch of generic glatiramer acetate have on reimbursement and market access challenges for MS brands in the EU5? 20 DRG Knows Multiple Sclerosis
When generic versions of current brands reach the EU5, optimizing and sustaining market access for emerging and existing brands will be increasingly challenging and ever-more convoluted in these costconstrained markets. DRG Knows M ultiple Sclerosis 21
DATA
INSIGHT
Interviewed payers across the EU5 seek evidence of improvement in medical benefit over existing agents to secure optimal reimbursement. They stress the need for direct comparator data to truly determine superiority.
Robust data supporting a new brand’s superior benefit headto-head versus an appropriate comparator is a key lever to garner optimal P&R terms for emerging MS DMTs in the EU5, especially as cheaper options penetrate the market. Furthermore, the launch of lower-cost generic alternatives may impact comparator preference for cost-savvy payers. Currently, cost per se is not seen as a key hurdle to uptake following admission to national reimbursement in a European market. However, payer policy at the regional/local level in highly cost-sensitive markets may demand initial use of cheaper options when these become available.
Surveyed neurologists rarely cite budgetary constraints as a reason for MS patients not to receive a DMT currently. However, some respondents — especially those in the UK — point to regional/local restrictions as a stumbling block, indicating payer policy at this level is impacting uptake to some extent.
22 DRG Knows Multiple Sclerosis
SOLUTION
FEATURES
BENEFITS
Our suite of solutions for staying on top of the MS market include:
Actionable data, analytics, and insights enable you to keep your finger on the pulse of what’s relevant to you in the MS market.
»» Primary market research »» Market access insight
»» Enables informed decision making »» Efficiently assess market scenarios »» Partnership with expert analysts
p
35
Physician & Payer Forum Physician and Payer Market Access Insights
DRG Knows M ultiple Sclerosis 23
What impact will the launch of generic glatiramer acetate have on the patient-prescriber relationship regarding digital healthcare? 24 DRG Knows Multiple Sclerosis
Neurologists understand that to succeed in an outcomes-based reimbursement model, they need to engage patients.
DRG Knows M ultiple Sclerosis 25
DATA
INSIGHT
Seven out of ten neurologists “somewhat” or “strongly” agreed that they were interested in using patient resources provided by manufacturers that would help them meet patient outcomes goals.
While only one-fifth of surveyed neurologists anticipated switching patients treated with Copaxone to generic glatiramer acetate (20 mg) six months after its launch, brand marketers can’t afford to neglect neurologists who are prioritizing other factors such as tolerability, patient engagement, and adherence among others and choosing branded treatments. For these segments of physicians, patients support services that leverage digital platforms such as mobile apps, patient portals, or remote care are likely to influence prescribing decisions.
Four in ten neurologists agreed that using digital technology to communicate directly with patients will improve patient outcomes, and as many said that they have increased their use of digital tools to communicate with patients over the past year.
26 DRG Knows Multiple Sclerosis
SOLUTION
FEATURES
BENEFITS
Our suite of solutions for staying on top of the MS market include:
Actionable data, analytics and insights enable you to keep your finger on the pulse of what’s relevant to you in the MS market.
»» Primary market research with physicians and consumers »» Digital healthcare insights
»» Enables informed decision making »» Efficiently assess market scenarios »» Partnership with expert analysts
p
40
Physician Digital Behavior Engage Today’s Digital Doctors
p
41
Consumer Digital Behavior Customized Insight by Therapeutic Category DRG Knows M ultiple Sclerosis 27
30
ChartTrendsî””
p
36
Analyzing Patient-Level Data
p
31
DecisionBase
Quantifying Lines of Therapy
p
37
Drug Development Opportunity Assessment
p
32
LaunchTrends
33
Pharmaview
p
38
34
Pharmacor
p
39
35
Physician & Payer Forum Physician and Payer Market Access Insights
Fingertip Formulary Gold standard Formulary Data
p
40
Analyzing and Forecasting
p
PatientBase Sizing Market Potential
Analyzing Corporate and Commercial Positioning
p
TreatmentTrends Analyzing Attitudes, Perceptions, and Prescribing Behavior
New Product Uptake and Impact
p
Treatment Algorithms
Physician Digital Behavior Engage Today’s Digital Doctors
p
41
Consumer Digital Behavior Customized Insight by Therapeutic Category
DRG Knows Multiple Sclerosis 29
PRODUCTS
p
PRODUCTS
ChartTrends Analyzing Patient-Level Data to Uncover the “Why” Behind Treatment Decisions
»» Uncover why physicians make certain choices about patient disease management »» Determine how physician attitudes compare against actual prescribing behavior »» Optimize your brand strategy and understand what’s happening at the patient level
30 DRG Knows Multiple Sclerosis
Understanding Crucial Unmet Needs for Drug Development Opportunities
»» Analyze an objective review of your drug or in-licensing candidate »» Fine-tune a drug’s positioning in the future disease market by understanding the competitive landscape of assets in clinical development »» Discover unmet needs in a given therapy area supported by KOL perspectives from physician and payer interviews
DRG Knows Multiple Sclerosis 31
PRODUCTS
DecisionBase
PRODUCTS
LaunchTrends Insights on Uptake and Impact of New Products on Market Dynamics
»» Assess the impact of a new drug launch against your commercially available product to hone messaging »» Track trial, adoption, and usage of newly launched products, including where it fits in the treatment algorithm »» Validate your brand positioning strategy
32 DRG Knows Multiple Sclerosis
PRODUCTS
Pharmaview Analyzing Corporate and Commercial Positioning in the Biopharmaceutical Industry
»» Assess the clinical and commercial position and performance of the top industry leaders with deep analysis supported by expert analyst insights »» Obtain a full view of your market with reliable and up-to-date product analysis and worldwide met sales roll ups by molecule, therapy area and company »» Understand M&A market events and dynamics with in-depth deals data
DRG Knows Multiple Sclerosis 33
PRODUCTS
Pharmacor Analyzing and Forecasting the Commercial Outlook for Drugs on the Market and in Research and Development
»» Understand the why and how of our revenue forecasts, including access to all “bottom-up” forecasting data • Patient share and populations • Generic erosion • Pricing • Dosing • Compliance »» Examine the commercial outlook of new brands, generics, and other key market events »» Accurately quantify market potential for competitive pipeline assets to optimize long-term disease strategies
34 DRG Knows Multiple Sclerosis
PRODUCTS
Physician & Payer Forum Global portfolio of brand-specific market access insights built on primary physician and payer research.
»» Pinpoint the market access levers and barriers that will drive or restrict your brand’s performance »» Inform your market access and launch plans with brand-specific, commercially-focused insights »» Integrate payer priorities, requirements, and views—as well as physicians’ preferences and prescribing habits—into your value messaging
DRG Knows Multiple Sclerosis 35
PRODUCTS
Treatment Algorithms Quantifying Lines of Therapy Through Patient-Level Claims Data
»» Understand treatment patterns when assessing new therapies, disease, and product areas »» Inform market opportunity assessments with analysis on market penetration and dynamics and product performance »» Drive product growth through accurate knowledge of your product’s positioning among the lines of therapy
36 DRG Knows Multiple Sclerosis
PRODUCTS
TreatmentTrends Analyzing Physicians’ Attitudes, Perceptions, and Self-Reported Prescribing Behavior
»» Analyze how brands are perceived, including sentiment of specific product attributes »» Optimize the impact of sales and marketing efforts »» Track therapeutic class and brand share
DRG Knows Multiple Sclerosis 37
PRODUCTS
PatientBase Sizing Market Potential with Gold-Standard Epidemiology Data
»» Know your market’s forecasts with robust, “bottom-up” sales and patientshare projections based on proprietary research from our industry-leading team of epidemiologists »» Understand key areas of opportunity using, including patient population stratification by: • Diagnosed and drug-treated status • Relevant clinical variables such as stage of disease at diagnosis and severity »» Identify disease growth trends in mature and emerging regions over a 10- or 20-year outlook period
38 DRG Knows Multiple Sclerosis
PRODUCTS
Fingertip Formulary Gold Standard Formulary Data and Interactive Tools Maximize Access Opportunities
RESTRICTIONS ANALYTICS
How are your brands covered vs. the competition? Where are your opportunities to influence placement?
ALERTS PUBLISHER
Where are your access hurdles — and what pull-through and promotion strategies can be leveraged?
How can you share current, cohesive messaging at the territory level easily and inexpensively?
How can your team leverage real-time updates to enhance plan discussions?
DRG Knows Multiple Sclerosis 39
PRODUCTS
Physician Digital Behavior Engage Today’s Digital Doctors with Taking the Pulse® Studies and advisory services focused on physician digital behavior globally.
»» Prioritize your resources towards the channels that physicians rely on most »» Understand your target physician audience with comprehensive, specialty-specific analysis »» Assess opportunities for providing content, services, and support to physicians online
40 DRG Knows Multiple Sclerosis
Customized Insight by Therapeutic Category with Cybercitizen Health. Studies and advisory services focused on consumer digital behavior in the U.S. and EU
»» Prioritize your resources towards the channels and digital tools that patients, caregivers, and info seekers rely on most »» Understand digital behavior and needs across the patient journey »» Identify opportunities to improve patient outcomes and adherence
DRG Knows Multiple Sclerosis 41
PRODUCTS
Consumer Digital Behavior
ANALYST BIOS VIRGINIA SCHOBEL, M.SC. is a Senior Director with the central nervous system/ophthalmology disorders group at Decision Resources Group. She has authored and managed syndicated primary market research projects across numerous indications, including multiple sclerosis, epilepsy, dry and wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, glaucoma, and uveitis. Prior to joining Decision Resources Group, Ms. Schobel worked as a market research manager and medical communications manager at Cephalon, Inc. (now Teva Pharmaceuticals Industries Ltd.) covering a diverse range of therapeutic areas, such as sleep/wake disorders, insomnia, anxiety, epilepsy, neuropathic pain, breakthrough cancer pain, ADHD, and alcohol dependency. She graduated from Hamilton College with a B.A. in Psychobiology and earned her M.Sc. in Neuroscience from the University of Michigan, where she studied the impact of drugs of abuse on brain plasticity.
JONATHAN W. SEARLES is a Senior Director with the central nervous system/ophthalmology disorders group at Decision Resources Group. Prior to joining Decision Resources Group, Mr. Searles received a B.A. degree, summa cum laude, from Brandeis University. While earning his bachelor of arts degree, Mr. Searles conducted research projects at the Harvard University Peabody Museum and at Brandeis.
42 DRG Knows Multiple Sclerosis
ANDREA S. WITT, PH.D. is the Therapy Lead of the central nervous system/ophthalmology disorders group at Decision Resources Group. Prior to this position, Dr. Witt managed portions of the CNS portfolio for six years and was an analyst for four years where her interests beyond specific CNS indications included the market potential for neuroprotectants and the impact of biomarkers on CNS markets. Dr. Witt’s research, analysis, and commentaries have appeared in Barron’s, Pharmaceutical Executive, PharmaVoice, Nature Medicine, and CNBC. Dr. Witt’s previous experience includes 10 years of scientific research conducted on neurodegenerative disorders at Harvard Medical School/Brigham and Women’s Hospital, Duke University, and the University of Texas-Southwestern Medical Center, where she earned her Ph.D. degree.
SONU KORI As a healthcare analyst at Decision Resources Group, Sonu Kori analyzes patient, physician, and payer health technology trends to identify opportunities for innovation and advise leadership at Fortune 500 biotech companies on data-driven solutions. She is passionate about understanding the patient journey and needs unique to therapeutic categories. She has analyzed trends in the U.S. and sixteen international markets. Prior, she concentrated in the business of healthcare in her MBA program at Washington University in St. Louis where she worked with a biomedical engineering team on commercialization strategies.
DRG Knows Multiple Sclerosis 43
Notes __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________
44 DRG Knows Multiple Sclerosis
__________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________________________________________________________________________________________
DRG Knows Multiple Sclerosis 45
Decision Resources Group is your trusted partner in identifying opportunities in the dynamic multiple sclerosis marketplace
Questions? Or contact us via email to learn more at inquiries@dresourcesgroup.com